作者
Jashodeep Datta, Megan Fracol, Matthew T McMillan, Erik Berk, Shuwen Xu, Noah Goodman, David A Lewis, Angela DeMichele, Brian J Czerniecki
发表日期
2016/2/1
期刊
JAMA oncology
卷号
2
期号
2
页码范围
242-246
出版商
American Medical Association
简介
Importance
There is a paucity of immune signatures identifying patients with human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer (IBC) at risk for treatment failure following trastuzumab and chemotherapy.
Objective
To determine whether circulating anti-HER2 CD4-positive (CD4+) T-helper type 1 (Th1) immunity correlates with recurrence in patients with completely treated HER2-positive IBC.
Design, Setting, and Participants
Hypothesis-generating exploratory translational analysis at a tertiary care referral center of patients with completely treated HER2-positive IBC with median (interquartile range) follow-up of 44 (31) months. Anti-HER2 Th1 responses were examined using peripheral blood mononuclear cells pulsed with 6 HER2-derived class II–promiscuous peptides via interferon-γ (IFN-γ) enzyme-linked immunospot assay.
Main Outcomes and Measures
T-helper type 1 response …
学术搜索中的文章
J Datta, M Fracol, MT McMillan, E Berk, S Xu… - JAMA oncology, 2016